ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,787Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 491

$1.92M Total Retail Price of All Prescriptions

Rank: 7 out of 491

962 Patients Receiving at Least One Drug in Part D
71%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 962 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

3% of this provider’s 7,256 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$178 was the average price of a prescription from this provider, compared to $218 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
GALANTAMINE HBR 588 535 10 1 36
GABAPENTIN 569 433 2 1
DONEPEZIL HCL 556 520 3 3
TOPIRAMATE 516 233 4 7
PRIMIDONE 490 398 10 5 11
ZONISAMIDE 476 258 10 6 22
NAMENDA 465 450 7 4
CARBIDOPA-LEVODOPA 344 334 8 2
VENLAFAXINE HCL ER 299 206 9 47
TRAZODONE HCL 276 209 10 31
DIVALPROEX SODIUM ER 256 154 11 29
CITALOPRAM HBR 235 189 12 18
HYDROCODONE-ACETAMINOPHEN 232 149 S3 13 6
CYMBALTA 226 149 14 13
LYRICA 207 137 15 10
AMITRIPTYLINE HCL 202 89 R 16 14
LEVETIRACETAM 181 77 17 5
PRAMIPEXOLE DIHYDROCHLORIDE 146 110 18 15
CLOPIDOGREL 139 112 19 33
QUETIAPINE FUMARATE 137 95 20 34
VERAPAMIL ER 132 81 21 112
WARFARIN SODIUM 131 126 22 73
AGGRENOX 112 71 23 44
PLAVIX 110 92 24 41
PROPRANOLOL HCL 104 79 25 30
PHENYTOIN SODIUM EXTENDED 93 34 26 17
MELOXICAM 90 46 27 37
AMANTADINE 86 68 28 35
OXCARBAZEPINE 86 52 28 26
ROPINIROLE HCL 83 53 30 9
SUMATRIPTAN SUCCINATE 76 23 31 55
SERTRALINE HCL 75 68 32 23
PYRIDOSTIGMINE BROMIDE 72 41 33 48
VENLAFAXINE HCL 72 62 33 133
TOPAMAX 72 0 33 81
KEPPRA 71 39 36 52
LAMOTRIGINE 70 42 37 8
TIZANIDINE HCL 69 18 38 20
EXELON 69 64 38 12
METHYLPREDNISOLONE 67 40 40 149
COPAXONE 66 13 41 39
CARISOPRODOL 64 20 R 42 24
GILENYA 62 0 43 97
METHYLERGONOVINE MALEATE 61 15 10 44 156
ZOLPIDEM TARTRATE 60 40 45 28
SELEGILINE HCL 59 53 46 62
PREDNISONE 59 31 46 46
MIRTAZAPINE 58 46 48 49
VIMPAT 57 0 49 19
CYCLOBENZAPRINE HCL 54 35 R 50 43
MAXALT 54 19 50 166
DIVALPROEX SODIUM 51 17 52 40
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 4, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.